From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for [electronic resource]
Producer: 20200720Description: e318-e326 p. digitalISSN:- 1549-490X
- Adult
- Afatinib -- economics
- Aged
- Aged, 80 and over
- Carcinoma, Non-Small-Cell Lung -- diagnosis
- Cost-Benefit Analysis
- Critical Pathways -- standards
- DNA Mutational Analysis -- standards
- Disease Progression
- Disease-Free Survival
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride -- economics
- Female
- Follow-Up Studies
- Gefitinib -- economics
- Guideline Adherence -- standards
- Humans
- Lung Neoplasms -- diagnosis
- Male
- Middle Aged
- Mutation
- Practice Guidelines as Topic
- Progression-Free Survival
- Prospective Studies
- Protein Kinase Inhibitors -- economics
- Time Factors
- Treatment Failure
- Assessment of Medication Adherence
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.